STUDY OF HV1 CHANNEL EXPRESSION IN CLINICAL SAMPLES OF BREAST CANCER THROUGH CLINICAL DATABASES ANALYSIS.

VENTURA, C; ENRIQUE N; MARTÍN, P; FELICE, JI; ISSOURIBEHERE, D; MILESI, V

Congreso; REUNIÓN DE SOCIEDADES DE BIOCIENCIAS 2020; 2020

Metabolic reprogramming, an emerging hallmark of cancer, conduces to a large production of acidic substances requiring the over expression of H+ extrusion cell structures. We have previously reported that proton channel (HVCN1) has a key role in this process in breast cancer cell lines and Jurkat T cells, and its inhibition induces apoptosis. The aim of this work was to analyze the HVCN1 channel expression (mRNA) in clinical samples of normal and neoplastic human mammary tissue and its correlation with key metabolic reprogramming-related gene increased in several types of cancers (Tanner et al., 2018, Cell Systems 7, 1?14). To this end, GEPIA and cBioPortal databases information was used. The analysis of GEPIA database showed that not significant differences of HVCN1 expression (Transcripts per Millon) appears between normal (N=291) and pathological (N=1085) mammary tissues. However, we observed different HVCN1 expression levels within tumor samples of the Breast Cancer METABRIC, Nature 2012 & Nat Commun 2016 study. Selecting samples in which HVCN1 mRNA level was major to one standard deviation of the median (high Hv1 group; N=250) and compared this group with the rest of the samples (control group; N=1653), we observed that the high Hv1 group contains a significantly increased number of triple negative and claudin-low samples respect to the control group (Chi-quadrate test, p